阿尔茨海默病的治疗药物作用机制研究进展  

Research progress on drugs in treatment of Alzheimer's disease

作　　者：万素馨[1] 方伟[1] WAN Su-xin;FANG Wei(Department of Pharmacy,Chongqing Three Gorges Central Hospital,Chongqing 404000,China)

机构地区：[1]重庆三峡中心医院药学部,重庆404000

出　　处：《现代药物与临床》2018年第12期3406-3410,共5页Drugs & Clinic

摘　　要：阿尔茨海默病的发病机制复杂,多数学者认为β-淀粉样蛋白级联反应、Tau蛋白过度磷酸化是导致该病发生发展的主要原因。目前该病的治疗药物如乙酰胆碱酯酶抑制剂(多奈哌齐、利斯的明、加兰他敏、石杉碱甲)和非竞争性N-甲基-D-天冬氨酸受体拮抗剂(美金刚)均以改善症状为主,尚无能延缓或终止疾病进展的药物。近年来国内外进行了大量以Aβ、Tau蛋白为靶点的治疗药物研究。主要对阿尔茨海默病治疗药物的研究进展进行综述。The pathogenesis of Alzheimer’s disease is complex. Most scholars believe that β-amyloid cascade and Tau protein hyperphosphorylation is the main cause of the development of the disease. The treatment of this disease such as acetylcholinesterase inhibitors(donepezil, rivastigmine, galantamine and and huperzine) and non-competitive N-methyl-D-aspartate receptor antagonists(memantine) are mainly to improve symptoms. There is no drug that can delay or stop the progression of the disease. In recent years, a large number of therapeutic drugs targeting Aβ and Tau proteins have been conducted worldwide. Research progress on drugs in treatment of Alzheimer’s disease is reviewed in this paper.

关 键 词：阿尔茨海默病 胆碱酯酶抑制剂 非竞争性N-甲基-D-天冬氨酸受体 AΒ蛋白 TAU蛋白 

分 类 号：R971[医药卫生—药品]